MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.200
-0.080
-6.25%
After Hours: 1.210 +0.01 +0.83% 19:03 04/16 EDT
OPEN
1.270
PREV CLOSE
1.280
HIGH
1.270
LOW
1.200
VOLUME
1.92M
TURNOVER
--
52 WEEK HIGH
2.940
52 WEEK LOW
1.010
MARKET CAP
142.74M
P/E (TTM)
-2.5052
1D
5D
1M
3M
1Y
5Y
AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure
Benzinga · 04/08 14:40
AcelRx Announces Investigator-Initiated Study Of DSUVIA In Patients Taking Buprenorphine Who Require A Surgical Procedure
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an
Benzinga · 04/08 12:37
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure
, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initia...
PR Newswire - PRF · 04/08 12:30
8-K: ACELRX PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- acrx20210330_8k.htm false 0001427925 0001427925 2021-03-30 2021-03-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/31 22:08
Press Release: AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors
Dow Jones · 03/31 12:30
AcelRx Pharmaceuticals Stock Is Estimated To Be Possible Value Trap
GuruFocus News · 03/30 22:07
ROCE Insights For AcelRx Pharmaceuticals
During Q4, AcelRx Pharmaceuticals's (NASDAQ:ACRX) reported sales totaled $738.00 thousand. Despite a 2.29% in earnings, the company posted a loss of $9.24 million. In Q3, AcelRx Pharmaceuticals brought in $1.37 million in sales but lost $9.04 million in ea...
Benzinga · 03/29 14:19
Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference
Exciting and insightful biotech news was front and center at the Benzinga Biotech Small Cap Conference, a two-day event that kicked off virtually Wednesday.
Benzinga · 03/25 18:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACRX. Analyze the recent business situations of Acelrx Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACRX stock price target is 5.21 with a high estimate of 9.00 and a low estimate of 0.8300.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 25.39M
% Owned: 21.34%
Shares Outstanding: 118.95M
TypeInstitutionsShares
Increased
28
2.11M
New
12
255.31K
Decreased
14
392.12K
Sold Out
6
305.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
Chief Executive Officer/Director
Vincent Angotti
Co-Founder/Director
Pamela Palmer
Chief Financial Officer
Raffi Asadorian
Other
Badri Dasu
Independent Director
Richard Afable
Independent Director
Marina Bozilenko
Independent Director
Mark Edwards
Independent Director
Stephen Hoffman
Independent Director
Howard Rosen
Independent Director
Mark Wan
No Data
About ACRX
AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.

Webull offers kinds of AcelRx Pharmaceuticals Inc stock information, including NASDAQ:ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.